WHO Calls For Countries To Regulate Use Of AI In Medicine
The World Health Organization warns that artificial intelligence tools require responsible management when deployed in the context of health, and has called for regulators and drug developers to engage in dialog about the safe use of such technology.
You may also be interested in...
The artificial intelligence revolution has arrived, but are pharmaceutical companies ready to meet the expectations of regulators? Lawyer Vincenzo Salvatore outlines the EU regulatory and policy developments that are relevant to the use of AI in the medicinal product lifecycle.
From rapidly identifying antigenic targets to automating clinical trials, AI has an important role to play in cutting vaccine development time down to 100 days, says Melanie Saville, executive director of R&D at CEPI.
Some innovative cancer drugs are not reaching eligible patients in the UK, despite securing positive reimbursement opinions from NICE. Eli Lilly explains how industry can be “part of the solution” through partnership initiatives.